01276 Overview

Top Hong Kong Stocks by Short Selling Ratios: S&P Global Market Intelligence reported the top ten Hong Kong stocks with the highest short selling ratios, highlighting CATL as the leader with a ratio of 27.016%.

Short Selling Data Overview: The report includes details on the number of shares borrowed, price changes, and short selling ratios for each stock, indicating significant short selling activity in the market.

Market Reactions: Stocks like COSCO SHIP HOLD and PING AN showed varying price changes, with PING AN having a notable short selling amount of $966.61M and a ratio of 18.980%.

Sector Impacts: The report also notes that external factors, such as the US-Iran conflict, are influencing market dynamics, particularly in sectors like oil and electric vehicles.

Market Performance: Hong Kong stocks showed mixed results, with the HSI rising 0.3% to close at 25,321, while the HSCEI and HSTECH fell by 0.4% and 0.7%, respectively, with a total market turnover of $321.872 billion.

Financial Sector Gains: Major financial stocks like HSBC and Standard Chartered saw increases of 2.4% and 2%, respectively, while AIA surged by 5.1%, indicating strong performance in the financial sector.

Pharmaceutical Sector Growth: The pharmaceutical industry experienced significant gains, with companies like Sino Biopharma and Akeso rising between 3% to over 7%, reflecting a robust market for healthcare stocks.

Automotive Sector Fluctuations: BYD Company faced a decline of 2.6%, contrasting with gains from other automakers like NIO and XPENG, which rose by 2.9% and 2.4%, respectively, highlighting volatility in the automotive sector.

Top Short Selling Stocks: S&P Global Market Intelligence identified the top ten Hong Kong stocks with the highest short selling ratios, highlighting significant borrowing activity relative to total shares issued.

CATL Performance: CATL (03750.HK) showed a short selling ratio of 16.502% with a total of $138.71 million borrowed, reflecting a slight price increase of 1.280% over the past week.

Jiangsu Express and Ping An: Jiangsu Express (00177.HK) had the highest short selling ratio at 48.169%, while Ping An (02318.HK) followed with a ratio of 29.427%, indicating substantial investor skepticism.

Overall Market Trends: The report includes various stocks with their respective short selling ratios and price changes, indicating mixed performance across the board, with some stocks experiencing significant declines.

Stock Performance: Several pharmaceutical stocks showed mixed performance, with HENGRUI PHARMA and HANSOH PHARMA experiencing gains, while SINO BIOPHARM saw a decline.

Short Selling Data: Short selling activity varied across companies, with SINO BIOPHARM having the highest short selling amount at $180.02M and a ratio of 40.682%.

Target Prices: Analysts have set target prices for various stocks, with HENGRUI PHARMA and HANSOH PHARMA rated as "Buy" with target prices of HK$98.3 and HK$51.5, respectively.

Market Sentiment: CSPC PHARMA received a "Neutral" rating, indicating a more cautious outlook compared to the "Buy" ratings for other companies listed.

Top Short Selling Stocks: S&P Global Market Intelligence identified the top 10 Hong Kong stocks with the highest short selling ratios, with CATL leading at 19.445% and Ping An at 34.425%.

Short Selling Data: The short selling ratios are calculated based on the percentage of shares borrowed relative to the total number of issued shares, with significant amounts of short selling observed across various companies.

Stock Performance: The report includes details on the number of shares borrowed, price changes over the past week, and the percentage change in short selling for each stock.

Market Insights: The data reflects investor sentiment and market trends, with notable interest in sectors such as materials, insurance, and consumer staples, as indicated by JPM's sector preferences.

4Q25 Revenue Expectations: Nomura anticipates HENGRUI PHARMA will achieve a 7% YoY increase in revenue to RMB8.3 billion, falling short of the market expectation of RMB9.5 billion, with drug sales expected to grow by 14% YoY.

Profit Margin Projections: The gross profit margin is estimated to rise to 86.5%, while the operating profit margin is projected to expand to 24.2%, leading to a 32% YoY increase in net profit attributable to shareholders, reaching RMB2.3 billion.

2026 Revenue Forecast: For 2026, Nomura forecasts an 18% revenue growth to RMB37.2 billion, with drug sales increasing by 9% YoY and external licensing revenue contributing RMB6 billion, alongside improved profit margins.

Target Price Adjustment: Nomura has reduced HENGRUI PHARMA's target price from HKD94.54 to HKD87.49 but maintains a Buy rating on the stock.